File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1440-1797.2011.01456.x
- Scopus: eid_2-s2.0-79959901598
- PMID: 21355950
- WOS: WOS:000292163500008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Dyslipidaemia in patients with lupus nephritis
Title | Dyslipidaemia in patients with lupus nephritis |
---|---|
Authors | |
Keywords | chronic kidney disease dyslipidaemia hydroxychloroquine lupus nephritis |
Issue Date | 2011 |
Publisher | Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEP |
Citation | Nephrology, 2011, v. 16 n. 5, p. 511-517 How to Cite? |
Abstract | Aim: There is little data on the prevalence and severity of dyslipidaemia in Asian patients with lupus nephritis (LN). Whether the dyslipidaemia in LN patients differs from subjects with comparable levels of renal impairment also remains undefined. Methods: Lipid profiles of 100 Chinese patients with quiescent LN (age 46.3 ± 9.3 years, 83% female, maintenance prednisolone dose 5.80 ± 2.43 mg/day) were studied and compared with 100 controls who had non-lupus non-diabetic chronic kidney diseases (CKD), matched for sex, age and renal function. Results: LN patients and CKD controls had similar renal function and proteinuria, while blood pressure was higher in controls. Twenty-five percent of LN patients and 17% of controls were receiving statin treatment. Despite this, 59% of LN patients and 46% CKD controls showed abnormal lipid parameters (P = 0.066). LN patients showed higher levels of total cholesterol (TC) and triglycerides (TG) than controls (5.28 ± 0.12 vs 4.86 ± 0.08 mmol/L, P = 0.004; and 1.62 ± 0.12 vs 1.20 ± 0.07 mmol/L, P = 0.002, respectively). More LN patients had abnormal TC, TG or low-density lipoprotein cholesterol (LDL-C) (54%, 16% and 38%; P = 0.016, = 0.005 and = 0.021, respectively). Hydroxychloroquine (HCQ) treatment was associated with lower TC, LDL-C and HDL-cholesterol. Conclusion: Dyslipidaemia is prevalent in LN patients and is more severe than controls with a similar degree of CKD despite disease quiescence, low steroid dose and low level of proteinuria. Concomitant corticosteroid and renal impairment are likely contributing factors. HCQ treatment is associated with reduced severity of dyslipidaemia in LN patients. Both systemic lupus erythematosus and chronic kidney disease are associated with excess vascular mortality. In this significant cohort of Asian patients with lupus nephritis, Chong et al. show that dyslipidaemia is common, even in inactive lupus nephritis, more common than in controls with a similar degree of chronic kidney disease. © 2011 Asian Pacific Society of Nephrology. |
Persistent Identifier | http://hdl.handle.net/10722/163381 |
ISSN | 2023 Impact Factor: 2.4 2023 SCImago Journal Rankings: 0.641 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chong, YB | en_US |
dc.contributor.author | Yap, DY | en_US |
dc.contributor.author | Tang, CS | en_US |
dc.contributor.author | Chan, TM | en_US |
dc.date.accessioned | 2012-09-05T05:30:42Z | - |
dc.date.available | 2012-09-05T05:30:42Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | Nephrology, 2011, v. 16 n. 5, p. 511-517 | en_US |
dc.identifier.issn | 1320-5358 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163381 | - |
dc.description.abstract | Aim: There is little data on the prevalence and severity of dyslipidaemia in Asian patients with lupus nephritis (LN). Whether the dyslipidaemia in LN patients differs from subjects with comparable levels of renal impairment also remains undefined. Methods: Lipid profiles of 100 Chinese patients with quiescent LN (age 46.3 ± 9.3 years, 83% female, maintenance prednisolone dose 5.80 ± 2.43 mg/day) were studied and compared with 100 controls who had non-lupus non-diabetic chronic kidney diseases (CKD), matched for sex, age and renal function. Results: LN patients and CKD controls had similar renal function and proteinuria, while blood pressure was higher in controls. Twenty-five percent of LN patients and 17% of controls were receiving statin treatment. Despite this, 59% of LN patients and 46% CKD controls showed abnormal lipid parameters (P = 0.066). LN patients showed higher levels of total cholesterol (TC) and triglycerides (TG) than controls (5.28 ± 0.12 vs 4.86 ± 0.08 mmol/L, P = 0.004; and 1.62 ± 0.12 vs 1.20 ± 0.07 mmol/L, P = 0.002, respectively). More LN patients had abnormal TC, TG or low-density lipoprotein cholesterol (LDL-C) (54%, 16% and 38%; P = 0.016, = 0.005 and = 0.021, respectively). Hydroxychloroquine (HCQ) treatment was associated with lower TC, LDL-C and HDL-cholesterol. Conclusion: Dyslipidaemia is prevalent in LN patients and is more severe than controls with a similar degree of CKD despite disease quiescence, low steroid dose and low level of proteinuria. Concomitant corticosteroid and renal impairment are likely contributing factors. HCQ treatment is associated with reduced severity of dyslipidaemia in LN patients. Both systemic lupus erythematosus and chronic kidney disease are associated with excess vascular mortality. In this significant cohort of Asian patients with lupus nephritis, Chong et al. show that dyslipidaemia is common, even in inactive lupus nephritis, more common than in controls with a similar degree of chronic kidney disease. © 2011 Asian Pacific Society of Nephrology. | en_US |
dc.language | eng | en_US |
dc.publisher | Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEP | en_US |
dc.relation.ispartof | Nephrology | en_US |
dc.rights | The definitive version is available at www.blackwell-synergy.com | - |
dc.subject | chronic kidney disease | - |
dc.subject | dyslipidaemia | - |
dc.subject | hydroxychloroquine | - |
dc.subject | lupus nephritis | - |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Cross-Sectional Studies | en_US |
dc.subject.mesh | Dyslipidemias - Drug Therapy - Epidemiology - Etiology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lipids - Blood | en_US |
dc.subject.mesh | Lupus Nephritis - Blood - Complications | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.title | Dyslipidaemia in patients with lupus nephritis | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yap, DY:desmondy@hku.hk | en_US |
dc.identifier.email | Chan, TM:dtmchan@hku.hk | en_US |
dc.identifier.authority | Yap, DY=rp01607 | en_US |
dc.identifier.authority | Chan, TM=rp00394 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1440-1797.2011.01456.x | en_US |
dc.identifier.pmid | 21355950 | - |
dc.identifier.scopus | eid_2-s2.0-79959901598 | en_US |
dc.identifier.hkuros | 209996 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-79959901598&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 16 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.spage | 511 | en_US |
dc.identifier.epage | 517 | en_US |
dc.identifier.isi | WOS:000292163500008 | - |
dc.publisher.place | Australia | en_US |
dc.identifier.scopusauthorid | Chong, YB=24773094400 | en_US |
dc.identifier.scopusauthorid | Yap, DY=25958532000 | en_US |
dc.identifier.scopusauthorid | Tang, CS=8681865300 | en_US |
dc.identifier.scopusauthorid | Chan, TM=7402687700 | en_US |
dc.identifier.issnl | 1320-5358 | - |